Breaking News: Metformin, a Diabetes Medication, May Hold the Key to Reducing AFib Recurrences
Could a simple diabetes drug be the answer to a healthier heart?
In a groundbreaking presentation at the American Heart Association's Scientific Sessions 2025, researchers revealed that metformin, a widely prescribed diabetes medication, might significantly reduce AFib (atrial fibrillation) recurrences in individuals with obesity. This study, led by Dr. Amish Deshmukh, opens up a new avenue of treatment possibilities.
But here's where it gets controversial: metformin, traditionally used for diabetes, is now being explored for its potential heart benefits. And this is the part most people miss - it's not just about diabetes anymore.
Understanding AFib and Its Impact
AFib, characterized by irregular and rapid heartbeats, is a common heart rhythm disorder. It can lead to serious complications like blood clots, stroke, and heart failure. Obesity is a significant risk factor, and those with AFib and obesity often face challenges in managing their condition.
The Metformin Connection
Metformin, a generic medication, has been a go-to treatment for Type 2 diabetes due to its effectiveness, long-standing use, and affordability. Previous research suggested that metformin could lower the risk of AFib in individuals with diabetes and obesity. Building on this, researchers wanted to explore its potential in preventing AFib recurrences post-ablation.
The META-AF Study
The Metformin as an Adjunctive Therapy to Catheter Ablation of Atrial Fibrillation (META-AF) study analyzed 99 adults with AFib and obesity or overweight. The goal? To determine if adding metformin to standard post-ablation care would be beneficial.
Here's what they found:
- AFib-Free Success: 78% of the metformin group remained AFib-free for a year, compared to 58% in the usual-care group.
- Reduced Need for Repeat Ablation: The metformin group had fewer patients requiring another ablation or electric shock to restore normal rhythm (6% vs. 16%).
- Fewer AFib Episodes: Metformin patients experienced less frequent AFib episodes during heart rhythm monitoring (8% vs. 16%).
- Medication Usage: Antiarrhythmia medications were used less frequently in the metformin group (8% vs. 18%).
- Weight Changes: Minimal weight changes were observed, consistent with prior metformin studies in non-diabetic individuals.
Implications and Future Directions
Dr. Deshmukh highlights that metformin treatment in non-diabetic individuals with obesity undergoing AFib ablation seems to lower the risk of recurrent AFib or atrial arrhythmias. However, the study also raises questions about the tolerability of metformin and the potential benefits of other diabetes and weight-loss medications, such as GLP-1 receptor agonists.
Obesity is a common risk factor for AFib, and recurrent episodes are more common in obese and overweight patients post-ablation. With AFib affecting over 6 million people in the U.S., according to the American Heart Association's 2025 statistics, the need for effective treatments is evident.
Dr. Deshmukh suggests a larger study to investigate metformin and other diabetes treatments, emphasizing the cardiovascular benefits these medications offer and the need to understand their specific benefits for arrhythmia patients.
Study Limitations
The study's limitations include its small size, single-center conduct, and potential lack of generalizability to different populations and ablation techniques.
Study Details
- Participants: 99 adults (average age 63; 70% men; mostly white) with AFib, 70% obese, and 30% overweight. 22% had a previous ablation, and 46% had AFib that resolved within a week without treatment.
- Exclusion Criteria: Participants with Type 1 or Type 2 diabetes, those with prediabetes (A1C 5.7%-6.4%), and those taking diabetes medications or for whom metformin was contraindicated.
- All participants: Were on blood thinners to lower stroke risk.
- Ablation Procedure: Performed in the pulmonary veins, a common AFib trigger area.
- Monitoring: After a 3-month healing period and reaching the maximum metformin dose, patients were monitored for AFib recurrences lasting at least 30 seconds.
- AFib Burden Calculation: Researchers calculated the AFib burden over one year (at 3 and 12 months) based on clinical monitoring, handheld monitors, pacemakers, and defibrillators.
- Metformin Discontinuation: A significant number (12 of 49) stopped metformin due to side effects or feeling well without it.
- Study Period: Conducted at the University of Michigan between 2021 and 2025.
This study opens up exciting possibilities for AFib treatment, but further research is needed to confirm these findings and address questions about long-term use and costs. What are your thoughts on this potential new treatment avenue? Feel free to share your opinions and experiences in the comments!
